National Cancer Institute - NCI Division of Cancer Treatment and ...

More documents

Recommendations

Info

DCTD has six major programs that work together to bring unique molecules from the laboratory bench to the patient bedside: ■ Biometrics Research Branch (BRB)— provides state-of-the-art statistical and biomathematical analyses for DCTD and other NCI components and performs research in the areas of statistical, mathematical, and computational sciences that is motivated and informed by real and important problems in current cancer research. Branch members provide leadership for the DCTD national research programs by formulating biomathematical approaches for analyzing genomic, proteomic, metabolomic, and other data emanating from the developmental therapeutics, diagnostics, imaging, radiation research, and clinical trials programs. ■ Cancer Diagnosis Program (CDP)— strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This program stimulates, coordinates, and funds specimen resources, databases related to those specimens, and research on diagnostics and improved technologies to better characterize tumors, so that cancer patients and their physicians can have access to a broader range of diagnostic information as they make clinical decisions. The laboratory tools CDP develops also help to maximize the impact of cancer treatments. ■ ■ ■ DCTD scientists support programs to pursue high-risk research that may yield great benefits for patients with cancer but may be too difficult or risky for industry or academia to undertake. ■ Cancer Imaging Program (CIP)— unites researchers in a team approach from disciplines as diverse as radiology, bioengineering, biology, chemistry, and physics. The program encourages researchers to integrate new imaging discoveries and developments into the study of cancer biology and into the clinical management of cancer and cancer risk. This translational research program is using new technologies to expand the role of imaging in noninvasive diagnosis, identification of disease subsets in patients, disease staging, and treatment monitoring. CIP supports and advises innovative developers in academia and private industry as they create the next generation of imaging technology, including molecular probes, optical technology devices, and new contrast agents. ■ Cancer Therapy Evaluation Program (CTEP)—functions as NCI’s primary clinical evaluator of new anticancer agents. Program staff members play a critical role in selecting promising agents to enter human clinical trials. In addition, the program evaluates new radiation and surgical methods, identifies biomolecular characteristics of malignant tumors that investigators may be able to exploit clinically, and administers the 11 cooperative research groups that unite researchers around the nation and the world in the pursuit of distinctive and effective new treatments for cancer. CTEP accomplishes its goals by administering, coordinating, and funding clinical trials, as well as sponsoring other research. The D I V I S I O N O F C A N C E R T R E A T M E N T A N D D I A G N O S I S ■ 3
Cancer Diagnosis Program Dr. Sheila Taube Associate Director Diagnostic Biomarkers and Technology Branch Dr. James Jacobson Branch Chief Diagnostics Evaluation Branch Dr. J. Milburn Jessup Branch Chief Resources Development Branch Vacant Branch Chief DCTD Management Biometric Research Branch Dr. Richard Simon Chief Cancer Imaging Program Dr. Daniel Sullivan Associate Director Diagnostic Imaging Branch Dr. C. Conrade Jaffe Branch Chief Image-Guided Intervention Branch Vacant Branch Chief Imaging Technology Development Branch Dr. Laurence Clarke Branch Chief Molecular Imaging Branch Dr. James Tatum Branch Chief 4 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6 Dr. James H. Doroshow Division Director Cancer Therapy Evaluation Program Dr. Michaele Christian Associate Director Clinical Grants and Contracts Branch Dr. Roy Wu Branch Chief Clinical Investigations Branch Dr. Jeffrey Abrams Branch Chief Clinical Trials Monitoring Branch Ms. Joan Mauer Branch Chief Investigational Drug Branch Dr. James Zwiebel Acting Branch Chief Pharmaceutical Management Branch Mr. Charles Hall, Jr. Branch Chief Regulatory Affairs Branch Dr. Dale Shoemaker Branch Chief Dr. Joseph Tomaszewski Deputy Director Developmental Therapeutics Program Dr. Jerry Collins Associate Director Biological Resources Branch Dr. Stephen Creekmore Branch Chief Biological Testing Branch Dr. Melinda Hollingshead Branch Chief Drug Synthesis and Chemistry Branch Dr. V. L. Narayanan Branch Chief Grants and Contracts Operations Branch Dr. Mary Wolpert Branch Chief Information Technology Branch Dr. Daniel Zaharevitz Branch Chief Natural Products Branch Dr. David Newman Acting Branch Chief Pharmaceutical Resources Branch Dr. B. Rao Vishnuvajjala Branch Chief Screening Technologies Branch Dr. Robert Shoemaker Branch Chief Toxicology and Pharmacology Branch Dr. Joseph Tomaszewski Branch Chief Radiation Research Program Dr. C. Norman Coleman Associate Director Clinical Radiation Oncology Branch Dr. Bhadrasain Vikram Branch Chief Molecular Radiation Therapeutics Branch Vacant Branch Chief Radiotherapy Development Branch Dr. Helen Stone Branch Chief
Page 1 and 2: National Cancer Institute U.S. DEPA
Page 3 and 4: ii ■ P R O G R A M A C C O M P L
Page 5 and 6: Clinical trials performed using an
Page 7: Dr. James H. Doroshow, Director Jam
Page 11 and 12: DCTD Research Grants 6 ■ P R O G
Page 13 and 14: disease-specific steering committee
Page 15 and 16: ■ The DCTD Developmental Therapeu
Page 17 and 18: P A R T N E R S H I P S A N D C O L
Page 19 and 20: laboratories. Dr. Kevin Dobbin, BRB
Page 21 and 22: ■ Gene expression patterns and pr
Page 23 and 24: Simon R. DNA microarrays for diagno
Page 25 and 26: Microarray Myths and Truths Myths
Page 27 and 28: target, is sensitive to the agent.
Page 29 and 30: O T H E R B I O S T A T I S T I C A
Page 31 and 32: almost inevitably leads to an invas
Page 33 and 34: Software and Technical Report Archi
Page 35 and 36: Biomarker Development Process Marke
Page 37 and 38: Strategic Partnering to Evaluate Ca
Page 39 and 40: C U R R E N T F U N D I N G O P P O
Page 41 and 42: P A R T N E R S H I P S A N D C O L
Page 43 and 44: several types of cancer TMAs have b
Page 45 and 46: Courtesy of NCI Visuals Online, Bil
Page 47 and 48: ■ Cooperative Human Tissue Networ
Page 49 and 50: Progress in many areas of cancer re
Page 51 and 52: Diagnostic Imaging Program in 1996,
Page 53 and 54: NCI Visuals Online, Terese Winslow,
Page 55 and 56: ■ Support development and deliver
Page 57 and 58: Small Animal Imaging Resource Progr
Page 59 and 60:
C U R R E N T F U N D I N G O P P O
Page 61 and 62:
Quick-Trials for Imaging and Image-
Page 63 and 64:
Association of American Cancer Inst
Page 65 and 66:
Food and Drug Administration and Ce
Page 67 and 68:
Dr. Edward A. Neuwelt, Oregon Healt
Page 69 and 70:
Virtual Colonoscopy Training Collec
Page 71 and 72:
Not only does CTEP identify promisi
Page 73 and 74:
The Clinical Trials Cooperative Gro
Page 75 and 76:
of pediatric cancers and therapeuti
Page 77 and 78:
the front line treatment of chronic
Page 79 and 80:
Quick-Trials for Novel Cancer Thera
Page 81 and 82:
Industry Collaborators Agent Name 7
Page 83 and 84:
Industry Collaborators Agent Name 7
Page 85 and 86:
NCI Visuals Online, George McGregor
Page 87 and 88:
provided for use in this clinical t
Page 89 and 90:
with or without bevacizumab (NSC #
Page 91 and 92:
Oxaliplatin-Based Regimen Permits S
Page 93 and 94:
egular checkups to look for lymph-n
Page 95 and 96:
NCI Visuals Online. Human lymphoma
Page 97 and 98:
T O O L S , P R O D U C T S , A N D
Page 99 and 100:
■ Clinical Trials Monitoring Bran
Page 101 and 102:
DTP’s staff and administered gran
Page 103 and 104:
therapeutics. Proposed exploratory
Page 105 and 106:
M A J O R O N G O I N G I N I T I A
Page 107 and 108:
National Cancer Institute. discover
Page 109 and 110:
C U R R E N T F U N D I N G O P P O
Page 111 and 112:
DTP oversees animal-production faci
Page 113 and 114:
disease can require considerable in
Page 115 and 116:
National Cancer Institute. commerci
Page 117 and 118:
The Type 1 Diabetes Rapid Access to
Page 119 and 120:
H I S T O R Y - M A R K I N G E V E
Page 121 and 122:
With this approach, patients are no
Page 123 and 124:
This included a camptothecin deriva
Page 125 and 126:
RRP supports research involving a v
Page 127 and 128:
Laredo Medical Center, Laredo, TX h
Page 129 and 130:
With TELESYNERGY® as a link, healt
Page 131 and 132:
Radiation Bioterrorism Research and
Page 133 and 134:
Enhanced Radiosensitivity The Molec
Page 135 and 136:
M E E T I N G S A N D W O R K S H O
Page 137 and 138:
Cancer Imaging Program 132 ■ P R
Page 139 and 140:
Cancer Therapy Evaluation Program,
Page 141 and 142:
Developmental Therapeutics Program,
Page 143 and 144:
Developmental Therapeutics Program,
show all

National Cancer Institute - NCI Division of Cancer Treatment and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?